Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

COMBAT

Financiado

Clearance Of Microbial Biofilms by Advancing diagnostics and Therapy

Every year chronic infections in patients due to biofilm formation of pathogenic bacteria are a multi-billion Euro burden to national healthcare systems. Despite improvements in technology and medical services, morbidity and morta... ver más

30/04/2022

HZI

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

HELMHOLTZZENTRUM FUR INFEKTIONSFORSCHUNG GMBH No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2022-04-30

ERC-2016-COG: ERC Consolidator Grant

I+D

Cerrada hace 8 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

HZI

2.00M€ | Lider

RENAULT ESPAÑA

3.00M€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

BIOFAGE Interaction Dynamics of Bacterial Biofilms with Bacteriophag... 1M€ Cerrado

OUTSMART-infection Microbiome centered prediction and prevention of recurrent i... 3M€ Cerrado

BIOinFILM Shedding light on the key molecular determinants regulating... 157K€ Cerrado

RTC-2015-3184-1 Nuevas estrategias para el control de infecciones nosocomial... 472K€ Cerrado

GEM-SEE-Achro GEM-SEE-Achro: Genomic Exploration—Mapping the Spread, Evolu... 159K€ Cerrado

OPATHY From Omics to Patient Improving Diagnostics of Pathogenic Y... 3M€ Cerrado

Duración del proyecto: 60 meses Fecha Inicio: 2017-04-24
Fecha Fin: 2022-04-30

Líder del proyecto

HELMHOLTZZENTRUM FUR INFEKTIONSFORSCHUNG GMBH No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Every year chronic infections in patients due to biofilm formation of pathogenic bacteria are a multi-billion Euro burden to national healthcare systems. Despite improvements in technology and medical services, morbidity and mortality due to chronic infections have remained unchanged over the past decades. The emergence of a chronic infection disease burden calls for the development of modern diagnostics for biofilm resistance profiling and new therapeutic strategies to eradicate biofilm-associated infections. However, many unsuccessful attempts to address this need teach us that alternative perspectives are needed to meet the challenges. The project is committed to develop innovative diagnostics and to strive for therapeutic solutions in patients suffering from biofilm-associated infections. The objective is to apply data-driven science to unlock the potential of microbial genomics. This new approach uses tools of advanced microbiological genomics and machine learning in genome-wide association studies on an existing unprecedentedly large dataset. This dataset has been generated in my group within the last five years and comprises sequence variation and gene expression information of a plethora of clinical Pseudomonas aeruginosa isolates. The wealth of patterns and characteristics of biofilm resistance are invisible at a smaller scale and will be interpreted within context and domain-specific knowledge. The unique combination of basic molecular biology research, technology-driven approaches and data-driven science allows pioneer research dedicated to advance strategies to combat biofilm-associated infections. My approach does not only provide a prediction of biofilm resistance based on the bacteria´s genotype but also holds promise to transform treatment paradigms for the management of chronic infections and by interference with bacterial stress responses will promote the effectiveness of antimicrobials in clinical use to eradicate biofilm infections.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores